logo-loader
viewAdmedus Ltd

Admedus files three new patents in the US for heart valve device

Earlier this month the company raised $6 million through a share placement.

multiple files with title patents focused upon
“We’re creating something special here, and the competition knows it.”

Admedus Ltd (ASX:AHZ)  has filed three new provisional patent applications in the US as part of its transcatheter aortic valve replacement (TAVR) research and development project.

TAVR is where a valve is placed into the heart via a catheter (usually inserted through the leg) to replace the aortic valve, eliminating the need for open-heart surgery.

Admedus’ new TAVR device is designed to reduce the risks associated with the insertion and placement of the valve.

READ: Admedus secures $6 million to expand medical technologies strategy

Underpinned by its clinically-superior ADAPT® tissue technology, Admedus’ TAVR aims to set a new benchmark in cardiovascular science and engineering.

The device will be looking to make an impact in the $3.5 billion market which is predicted to reach $5 billion by 2020.

The patent lodgements follow on from Admedus recently entering into an agreement with a renowned European reference laboratory to commence the first TAVR animal trials in July.

READ: Admedus progressing to animal trials of its unique heart valve device

Admedus’s CEO Wayne Paterson said: “As I’ve said previously, with this project Admedus wants to set a new global standard in innovation and patient care, built on the absolute cutting-edge of medical science and engineering.”

“With the design of each component, we are addressing vast areas of unmet need in durability, position and placement, cost-efficiency and improved patient outcomes - literally developing novel IP from one tip of the TAVR device to other.

“This is what makes the filing of these patent applications so critically important, we need to protect our significant investment and IP as competitors become increasingly aware of, and interested in, our progress.

“We’re creating something special here, and the competition knows it.”

Quick facts: Admedus Ltd

Price: 0.0865 AUD

ASX:AHZ
Market: ASX
Market Cap: $51.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read